Safety and efficacy of autologous hematopoietic stem-cell transplantation following natalizumab discontinuation in aggressive multiple sclerosis.
Alice MariottiniC InnocentiB ForciE MagnaniC MechiA BarilaroR NistriA FaniR SaccardiL MassacesiA M RepicePublished in: European journal of neurology (2018)
These data suggest that an aggressive therapy should be established after NTZ with the shortest possible wash-out period. aHSCT after 6 months from NTZ withdrawal appears to be safe.